Steris (STE) Upgraded to Buy: Here's Why
Steris (STE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Interpreting Steris (STE) International Revenue Trends
Examine the evolution of Steris' (STE) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.
STERIS plc (STE) Q2 2026 Earnings Call Transcript
STERIS plc ( STE ) Q2 2026 Earnings Call November 6, 2025 9:00 AM EST Company Participants Julie Winter - Vice President of Investor Relations & Corporate Communications Karen Burton - Senior VP, CFO & Chief Accounting Officer Daniel Carestio - President, CEO & Director Conference Call Participants Brett Fishbin - KeyBanc Capital Markets Inc., Research Division Patrick Wood - Morgan Stanley, Research Division Jason Bednar - Piper Sandler & Co., Research Division Michael Matson - Needham & Company, LLC, Research Division Michael Polark - Wolfe Research, LLC Presentation Operator Hello, and thank you for standing by. My name is Bella, and I will be your conference operator today.
STE Stock Gains on Q2 Earnings and Revenue Beat, '26 EPS View Up
STERIS posts strong Q2 results with earnings and revenue beats, margin expansion, and a raised 2026 EPS outlook.
Here's What Key Metrics Tell Us About Steris (STE) Q2 Earnings
Although the revenue and EPS for Steris (STE) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Steris (STE) Surpasses Q2 Earnings and Revenue Estimates
Steris (STE) came out with quarterly earnings of $2.47 per share, beating the Zacks Consensus Estimate of $2.38 per share. This compares to earnings of $2.14 per share a year ago.
Seeking Clues to Steris (STE) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Steris (STE), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2025.
Ethic Inc. Purchases 79 Shares of STERIS plc $STE
Ethic Inc. lifted its position in shares of STERIS plc (NYSE: STE) by 4.8% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,716 shares of the medical equipment provider's stock after purchasing an additional 79 shares during the period.
STERIS to Report Q2 Earnings: Here's What to Expect
STE is set to post fiscal Q2 results on Nov. 6, with estimates pointing to solid revenue and earnings growth across key segments.
Here's Why Steris (STE) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Steris (STE) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Steris: Marginal Gains Capitalized At Higher Rates, Reiterate Buy
STERIS remains a high-quality, defensive cash recycler with diversified growth, expanding margins, strong cash conversion, and disciplined capital deployment. Q1 FY'26 results showed broad-based 9% revenue growth, margin expansion across all segments, and raised full-year guidance, supporting my positive investment view. Valuation is fair with upside to $270–$300/share; the company excels at recycling cash into earnings, dividends, and buybacks, despite modest top-line growth.
